News & Events – Page 2 – www.brainwork.md

7th February 2022

Multiple sclerosis management in the elderly

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-06-20220207_Article4_Article4.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 7th February 2022 14th February 2022

The life expectancy in multiple sclerosis (MS) continues to increase and is now comparable to that of the general population.1 This increase comes with the…

Samyuktha Pillai, PhD
0
0

3rd February 2022

Preliminary results from stem cell transplantation as an MS therapy in Switzerland

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article1.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

Autologous hematopoietic stem cell transplantation (aHSCT) has been used in the treatment of multiple sclerosis (MS) since 1995 and was approved in Switzerland in June…

Samyuktha Pillai, PhD
0
0

3rd February 2022

MS 2022: Upcoming therapies, and their pros and cons

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article2.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

The repertoire of available multiple sclerosis (MS) disease modifying therapies (DMTs) is constantly growing. In recent years, there have been several new DMTs that have…

Samyuktha Pillai, PhD
0
0

MS State of the Art Symposium 2022

The MS State of the Art Symposium will take place on 29th January 2022. This is the most important scientific MS event in Switzerland. Stay…

https://www.brainwork.md/tag/ms-state-of-the-art-symposium-2022/

https://www.brainwork.md/content/uploads/2022/01/Brainwork-MS-State-of-the-Art-Symposium-2022.jpg 1500 1125 Samuel Krebs Samuel Krebs https://secure.gravatar.com/avatar/fc8fd5388a4b0dab003e549cd46f68f2?s=96&d=mm&r=g 28th January 2022 4th February 2022

26th January 2022

Key pharmacological recommendations for hospitalised COVID‑19 patients: A German national treatment guidance

https://www.brainwork.md/content/uploads/2022/01/Brainwork-Key-pharmacological-recommendations-for-hospitalised-COVID‑19-patients-a-German-national-treatment-guidance.jpg 1500 1000 Noreen Hussain, PharmD Noreen Hussain, PharmD https://secure.gravatar.com/avatar/3f9b130bd961103113f7d0b1a97099e0?s=96&d=mm&r=g 26th January 2022 4th February 2022

During the current coronavirus 2019 disease (COVID-19) pandemic, research is being developed and disseminated at an accelerated pace.1 The constant influx of data can be…

Noreen Hussain, PharmD
0
0

20th January 2022

Cognitive deficits related to COVID-19: The challenge of measuring association

https://www.brainwork.md/content/uploads/2022/01/Brainwork-Cognitive-deficits-related-to-COVID-19-The-challenge-of-measuring-association-scaled.jpg 2560 1707 Akshar Patel Akshar Patel https://secure.gravatar.com/avatar/a5428a1217919bac06fa011ae31e3736?s=96&d=mm&r=g 20th January 2022 24th January 2022

There has been increasing worry about possible cognitive consequences related to COVID-19 and recent case studies have revealed neurological problems in severely affected patients.1 Growing…

Akshar Patel
0
0

14th January 2022

What are the implications for the third COVID-19 vaccine on CD-20-depleted people with MS – Oliver Findling reports

https://www.brainwork.md/content/uploads/2022/01/Brainwork-what-are-the-implications-for-the-third-COVID-19-vaccine-on-CD-20-depleted-people-with-MS.jpg 1500 1001 Shawn Haigh Shawn Haigh https://secure.gravatar.com/avatar/d4448de12cafdc782da0f7b369642f0e?s=96&d=mm&r=g 14th January 2022 25th January 2022

In a guest post on “The MS Blog,” Dr Oliver Findling summarised a recent study on which he was the principal investigator: Humoral Immune Response…

Shawn Haigh
0
0

5th January 2022

Speaking to Prof. Mary Reilly – “Complex cases are part of the attraction“

https://www.brainwork.md/content/uploads/2022/01/Brainwork-Interview-Prof-Mary-Reilly-fp.jpg 1300 1329 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 5th January 2022 5th January 2022

Prof. Mary Reilly is a consultant neurologist at the National Hospital for Neurology and Neurosurgery and a professor of clinical neurology, heading the division of…

Anna Stelling, PhD
0
0

3rd December 2021

Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis

https://www.brainwork.md/content/uploads/2021/12/Brainwork-Long-term-survival-participants-CENTAUR-trial-sodium-phenylbutyrate-taurursodiol-amyotrophic-lateral-sclerosis.jpg 960 640 Brainwork Brainwork https://secure.gravatar.com/avatar/c65b553db7114a8936dd574a5706aa6f?s=96&d=mm&r=g 3rd December 2021 3rd December 2021

The CENTAUR phase 2, randomised, placebo-controlled trial included patients with amyotrophic lateral sclerosis (ALS) who received a fixed dose formulation of sodium phenylbutyrate-taurursodiol (PB-TURSO). The…

Brainwork
0
0

29th October 2021

Getting the complete clinical picture: A closer look at smouldering MS

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-02_inflammation-.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 24th January 2022

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS,…

Howard Donohue, PhD
0
0

29th October 2021

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-04_antibody.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus,…

Howard Donohue, PhD
0
0

29th October 2021

Aquaporin-4-positive neuromyelitis optica spectrum disorder: A favourable long-term benefit-risk profile of eculizumab treatment

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-06-20211013_illustration-05_nerve.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease that typically affects the optic nerves and spinal cord.1,2 At least two-thirds of cases are…

Howard Donohue, PhD
0
0